Integral Diagnostics (Integral Diagnostics) EBIT : $-21.6 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Integral Diagnostics EBIT?

Integral Diagnostics's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was $-36.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Integral Diagnostics's annualized ROC % for the quarter that ended in Dec. 2023 was 5.16%. Integral Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -38.88%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Integral Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3.49%.

Integral Diagnostics EBIT Historical Data

The historical data trend for Integral Diagnostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integral Diagnostics EBIT Chart

Integral Diagnostics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT

Get a 7-Day Free Trial

25.56

30.24

41.39

23.22

32.89

Integral Diagnostics Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial												14.47	9.00	18.25	14.73	-36.38

Competitive Comparison of Integral Diagnostics's EBIT

For the Diagnostics & Research subindustry, Integral Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integral Diagnostics's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Integral Diagnostics's EV-to-EBIT falls into.

Integral Diagnostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-21.6 Mil.

Integral Diagnostics (OTCPK:ITGDF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Integral Diagnostics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	26.654 * ( 1 - -1.5% )	/	( (555.566	+	493.921)	/ 2 )
=	27.05381	/	524.7435
=	5.16 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	563.095	-	20.903	-	( 22.721	-	max(0, 55.481	-	42.107	+	22.721	))
=	555.566

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	499.195	-	18.929	-	( 12.04	-	max(0, 57.611	-	43.956	+	12.04	))
=	493.921

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Integral Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-72.758	/	( ( (189.568 + max(-24.701, 0))	+	(184.744 + max(-13.725, 0)) )	/	2 )
=	-72.758	/	( ( 189.568	+	184.744 )	/	2 )
=	-72.758	/	187.156
=	-38.88 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(14.764	+	1.24	+	3.589)	-	(20.903	+	0	+	23.391)
=	-24.701

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(14.961	+	1.24	+	15.715)	-	(18.929	+	0	+	26.712)
=	-13.725

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Integral Diagnostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-21.645	/	620.476
	=	-3.49 %

Integral Diagnostics EBIT Related Terms

Thank you for viewing the detailed overview of Integral Diagnostics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Integral Diagnostics (Integral Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Integral Diagnostics Ltd (OTCPK:ITGDF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

IDX:Australia

Address

45 William Street, Suite 9.02, Level 9, Melbourne, VIC, AUS, 3000

Website

http://www.integraldiagnostics.com.au

Integral Diagnostics is Australia's fourth-largest diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.